BIOCHEMICAL AND HISTOPATHOLOGICAL EVALUATION OF GLYCIRRHIZIN AND BOSWELLIA CARTERII EXTRACT ON RAT LIVER INJURY

Farid A. Badria*1, Wael E. Houssen1, Eman M. El-Nashar2 and Shehta A. Said3
Pharmacognosy1 and Pharmacology 3 Departments, Faculty of Pharmacy, Mansoura University, Mansoura (Egypt)
Histology and Cytology2 Department, Benha Faculty of Medicine, Zagazig (Egypt)

(Received, May 15, 2003)

ABSTRACT

The hepatoprotective effect of glycyrrhizin (GL) and ethanolic extract of Boswellia carterii (BC) rat liver injury induced by CCl4 was studied. Rats were administered orally with CCl4 (once a week for 4 weeks with the following doses; 0.16, 0.24, 0.32 and 0.4 ml.kg⁻¹ for first, second, third and fourth week respectively. Two CCl4 challenged groups were concomitantly administered orally with GL (100 mg.kg⁻¹, once daily for 4 weeks) and BC (50 mg.kg⁻¹, once daily for 4 weeks). Serum activities of alanine aminotransferase (ALT) and alkaline phosphatase (AP) and serum concentrations of total bilirubin and albumin were measured and histopathological changes in livers were examined. The elevation of serum ALT, AP and bilirubin was delayed and attenuated and hepatic parenchymal swelling and necrosis produced by CCl4 were ameliorated by both GL and BC. The results showed that both oleanene-type triterpenes (GL and BC) can protect rats against CCl4-induced hepatotoxicity in subchronic CCl4 exposure, and the protection may be partly related to decrease of CCl4–induced inflammation and additional deposition of collagen in target organs.

KEY WORDS: Glycyrrhizin, Boswellia carterii, Oleanene triterpenes, Liver injury.

INTRODUCTION

Although hepatotoxins-induced liver lesions may be reversed in the early stages, they can not be healed only by removal of the toxin after critical periods, highlighting the need of effective remedies for liver diseases. In our search for plant constituents with antihepatotoxic potential, both glycyrrhizin and ethanolic extract of Boswellia carterii (BC) proved to exhibit a protective effect against (CCl4)-induced hepatotoxicity. Glycyrrhizin (Glz), an Oleanene triterpenoid glycoside obtained from the roots of Glycyrrhiza glabra, was known with its preventive effect against several forms of experimental liver injury in animals¹. Glz is widely used to treat hepatocellular injury especially hepatitis2-4. It inhibits the activity of 11-beta-hydroxysteroid dehydrogenase, PGE2 production

![Chemical structures of glycyrrhizin and boswellic acids.](image-url)

Fig. 1: Chemical structures of glycyrrhizin and boswellic acids.

\[ R_1 = \text{D-glucuronic acid-D-glucuronic acid} \]
\[ 1 \ R_2 = \text{H} \quad R_3 = \text{H}_2 \quad \beta-\text{boswellic acid.} \]
\[ 2 \ R_2 = \text{Ac} \quad R_3 = \text{H}_2 \quad 3\text{-O-acetyl-}\beta-\text{boswellic acid.} \]
\[ 3 \ R_2 = \text{H} \quad R_3 = \text{O} \quad 11\text{-keto-}\beta-\text{boswellic acid.} \]
\[ 4 \ R_2 = \text{Ac} \quad R_3 = \text{O} \quad 3\text{-O-acetyl-11-keto-}\beta-\text{boswellic acid.} \]
by macrophages and modifies arachidonic acid metabolism. It also has antioxidant activity². Moreover, it was noticed that glycyrrhizin treatment blunts ALT elevations and impedes fibrosis in animals ³,⁴. Boswellic acid (BA) and its analogues were identified as the active principles of Boswellia species⁵. Safayhi and Sailer showed that boswellic acid might be a rich natural source as anti-inflammatory drug development[?]. It was reported that BA showed a significant protection against galactosamine/endotoxin induced hepatitis in mice [//]. Due to the structure similarity between boswellic acid and glycyrrhizin (Fig. 1), we suggest that boswellic acid may have a potential antihapatotoxic activity. So in this work, the hepatoprotective effects of glycyrrhizin and ethanolic extract of BC were biochemically and histopathologically evaluated.

MATERIALS AND METHODS

Reagents:
Glycyrrhizin solution (2.5%) was prepared by dissolving glycyrrhizin sodium salt (Aldrich, USA) in distilled water. Ethanolic extract of BC was prepared in our lab and given as o/w emulsion using cremophore (2%) as emulsifier. Cremophore (2%) was previously tested on a separate group of animals and proved to have no effect on liver function (Unpublished data). All other reagents were of analytical grade.

Animals:
Six groups of adult male albino rats (150-200 g) were obtained from????, each consisting of 10 rats, were used to perform this experiment. One group is taken as control and others received CCl₄, GL, GL+CCl₄, BC and BC+CCl₄. BC extract and GL were given orally once daily for four weeks at 50 mg.kg⁻¹ and 100 mg.kg⁻¹ respectively. CCl₄ was administered orally once a week for four weeks with the following doses (0.16, 0.24, 0.32 and 0.4 ml.kg⁻¹ for first, second, third and forth week respectively) [6]. All CCl₄ doses were mixed with corn oil (1:1 v/v) before administration to alleviate irritation.

Biochemical evaluation of liver function:
After 4 weeks experiment, rats were sacrificed and blood was collected for biochemical analysis. Serum was separated for estimation of alanine aminotransferase (ALT) activity⁷, alkaline phosphatase (AP) activity⁸, total bilirubin⁹ and albumin¹⁰.

Histopathological studies:
Liver specimens of all groups were fixed in neutral buffered formalin, conventionally processed, paraffin embedded and sectioned at 4 microns¹¹. The obtained slides were stained with Haematoxylin and Eosin (Hx. & E.) and Masson trichrome stains.

Statistical analysis:
Values are expressed as means ± S.E. Means were compared using Student’s (t) test. Differences were considered significant when p < 0.05.

Results
A- Biochemical results:
Effect on alanine aminotransferase (ALT) and alkaline phosphatase (AP) activities:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>ALT (units/ml)</th>
<th>AP (Kind and king units %)</th>
<th>Bilirubin (mg %)</th>
<th>Albumin (g %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>33.5 ± 02.51</td>
<td>21.5 ± 6.04</td>
<td>0.22 ± 0.09</td>
<td>3.6 ± 0.18</td>
</tr>
<tr>
<td>CCl₄</td>
<td>129.0 ± 12.88 *</td>
<td>51.4 ± 6.24 *</td>
<td>0.72 ± 0.16 **</td>
<td>3.5 ± 0.15</td>
</tr>
<tr>
<td>BC (50 mg.kg⁻¹)</td>
<td>35.3 ± 03.71</td>
<td>33.1 ± 7.31</td>
<td>0.38 ± 0.12</td>
<td>3.18 ± 0.17</td>
</tr>
<tr>
<td>BC + CCl₄ (50 mg.kg⁻¹)</td>
<td>43.0 ± 02.84 ***</td>
<td>29.6 ± 3.60 ***</td>
<td>0.43 ± 0.07</td>
<td>3.4 ± 0.01</td>
</tr>
<tr>
<td>GL (100 mg.kg⁻¹)</td>
<td>29.8 ± 01.32</td>
<td>37.8 ± 8.52</td>
<td>0.41 ± 0.05</td>
<td>3.3 ± 0.15</td>
</tr>
<tr>
<td>GL + CCl₄ (100 mg.kg⁻¹)</td>
<td>63.6 ± 08.34 ***</td>
<td>27.4 ± 0.03 ***</td>
<td>0.82 ± 0.12 **</td>
<td>3.6 ± 0.18</td>
</tr>
</tbody>
</table>

* Significantly different from control group (p < 0.01) using Student’s (t) test.
** Significantly different from control group (p < 0.05) using Student’s (t) test.
*** Significantly lower than that of CCl₄-treated group (p < 0.01) using Student’s (t) test.
The CCl$_4$ group showed a significant (p < 0.01) increase in serum activities of ALT and AP compared to the control group. Administration of BC extract or GL showed no significant alteration in ALT and AP activities from the control values. Co-administration of either BC extract or GL with CCl$_4$ resulted in a significant decrease in ALT and AP activities compared to CCL$_4$-treated group (Table 1).

**Effect on total bilirubin concentration:**

CCl$_4$ group showed a significant (p < 0.05) increase in bilirubin level compared to the control group. Neither BC extract nor GL significantly altered total bilirubin level from the control value. Only BC extract showed a marked reduction in total bilirubin level.

**Effect on serum albumin level:**

Neither CCl$_4$ administration nor treatments with BC extract or GL significantly altered albumin levels.

**B-Histopathological observations:**

Rats of CCl$_4$ group showed cirrhotic changes in their livers manifested by doubling of central veins and dilatation of blood sinusoids. Also, cirrhotic nodules, perportal fibrosis and extensive degeneration of hepatocytes were markedly distinct. On the other hand, those pretreated with either BC extract or GL showed a marked decrease of these cirrhotic changes. Animals treated with either BC extract (50 mg.kg$^{-1}$) or GL (100 mg.kg$^{-1}$) alone showed a normal liver architecture.

**Discussion and Conclusion**

The ability of a hepatoprotective compound to reduce the injurious effects or to preserve the normal hepatic physiological mechanisms, which have been disturbed by a hepatotoxic, is the index of its protective effect. Carbon tetrachloride (CCl$_4$) is long known to produce liver injury. The mechanism by which CCl$_4$ induces hepatotoxicity was attributed to the release of free radicals, which could interact with other lipid-rich cells producing alteration in the structure and function of the liver cells$^{12}$. In 1982, Proctor and Chatamra$^6$ stated that intragastric CCl$_4$ administration is preferred than the subcutaneous or the inhalation routes to induce liver toxicity in rats. This is because, the inhalation method suffers from the fact that CCl$_4$ will pass from the lung to the left atrium with subsequent high peak concentration of CCl$_4$ in the arterial blood. This high concentration is much more likely to produce extrahepatic (e.g. renal and cerebral) effects before the CCl$_4$ is sufficiently extracted and concentrated in the liver while subcutaneous route of administering CCl$_4$ is a very slow and unreliable method of producing cirrhosis. On the other hand, intragastric administration of CCl$_4$ assures that the major part of it goes to the liver through the portal vein before entering the arterial system as rat liver selectively concentrates CCl$_4$ in ratio of 13:1 with respect to the blood$^6$. Moreover, the same authors$^6$ observed a variable response in rats toward CCl$_4$ toxicity with respect to time. This is due to two factors – the increasing age of rats which reduces the sensitivity to CCl$_4$$^{15}$, and the increasing damage of the liver with each dose of CCl$_4$, which reduces the amount of cytochrome P$_{450}$/CCl$_4$ "toxin" effect$^{10}$.

Bilirubin is one of the most useful biochemical clues to the severity of necrosis$^{18}$, and its accumulation is a measure of binding, conjugation and excretory capacity of hepatocytes relative to the erythrocytes degradation rate$^{19}$.

In this study, both GL and BC extract were tested for their hepatoprotective effects against CCl$_4$-induced liver injury. Many investigators have reported on the hepatoprotective effects of GL$^{4,20,21}$. In 1984, Kiso et al$^{22}$ have showed that GL inhibits cytotoxicity caused by carbon tetrachloride (CCl$_4$) in primary cultured rat hepatocytes in vitro$^{22}$. Due to the close similarity in chemical structure between GL and Boswellic acids (the main active constituents of Boswellia species), we have investigated the hepatoprotective effect of BC extract. GL and BC extract were administered orally once daily for four weeks at 100 mg.kg$^{-1}$ and 50 mg.kg$^{-1}$ respectively with or without CCl$_4$, hepatotoxic.

The obtained results indicated significant protective effects of GL and BC against CCl$_4$-induced hepatotoxicity at dose levels of 100 and 50 mg.kg$^{-1}$ respectively.

Under given route of application, GL and BC seem to preserve the integrity of liver cell membrane as proved by the significant reduction of the CCl$_4$-induced rise of ALT and AP levels. They also have the ability to prevent CCl$_4$-induced hepatocellular necrosis and to maintain the normal functional status of the liver as proved by the significant reduction of the CCl$_4$-induced rise in serum bilirubin and by the histopathological study. Astonishingly, in the present study, no change was observed in the serum albumin levels in all groups. This might probably be due to the long biological half life time of albumin as it is not altered in acute and sub-chronic liver damage$^{19}$.
This study demonstrated that GL and BC under the given route and schedule of treatment are hepatoprotective drugs in rats and can significantly reduce the hepatic damage induced by CCl₄ intoxication.

REFERENCES